ATE294159T1 - Herstellung von nichtkristallinem atorvastatin?calcium - Google Patents

Herstellung von nichtkristallinem atorvastatin?calcium

Info

Publication number
ATE294159T1
ATE294159T1 AT02734878T AT02734878T ATE294159T1 AT E294159 T1 ATE294159 T1 AT E294159T1 AT 02734878 T AT02734878 T AT 02734878T AT 02734878 T AT02734878 T AT 02734878T AT E294159 T1 ATE294159 T1 AT E294159T1
Authority
AT
Austria
Prior art keywords
atorvastatin
crystalline
calcium
salt
preparation
Prior art date
Application number
AT02734878T
Other languages
English (en)
Inventor
Gorazd Sorsak
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of ATE294159T1 publication Critical patent/ATE294159T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02734878T 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium ATE294159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (1)

Publication Number Publication Date
ATE294159T1 true ATE294159T1 (de) 2005-05-15

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02734878T ATE294159T1 (de) 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium

Country Status (27)

Country Link
US (2) US6750353B2 (de)
EP (1) EP1373202B1 (de)
JP (1) JP4336106B2 (de)
KR (1) KR100882066B1 (de)
CN (1) CN1260213C (de)
AT (1) ATE294159T1 (de)
AU (1) AU2002219455B2 (de)
BG (1) BG108017A (de)
BR (1) BR0206637A (de)
CA (1) CA2435954C (de)
CZ (1) CZ20031988A3 (de)
DE (1) DE60203894T2 (de)
DK (1) DK1373202T3 (de)
EE (1) EE05270B1 (de)
ES (1) ES2240748T3 (de)
HR (1) HRP20030575B1 (de)
HU (1) HU227535B1 (de)
IL (2) IL157068A0 (de)
MX (1) MXPA03006548A (de)
PL (1) PL209428B1 (de)
RS (1) RS51010B (de)
RU (1) RU2324679C2 (de)
SI (2) SI20814A (de)
SK (1) SK286593B6 (de)
UA (1) UA73829C2 (de)
WO (1) WO2002059087A1 (de)
ZA (1) ZA200305307B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2431068C (en) 2000-12-27 2008-06-10 Ciba Specialty Chemicals Holding Inc. Crystalline forms of atorvastatin
EP1365995A2 (de) * 2001-02-27 2003-12-03 Council of Scientific and Industrial Research Ätherisches öl enthaltende zusammensetzungen für trinkwasserentkeimung
CZ20033478A3 (cs) 2001-06-29 2004-10-13 Warner@Lambertácompanyállc Krystalické formy vápenaté soli }@�B [R@}RgŹRgB]@}@fluorofenylB@betaŹ@delta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové kyseliny }atorvastatinB
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
KR20090045420A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005003138A2 (en) 2003-07-02 2005-01-13 EGIS Gyógyszergyár Rt. Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
WO2005005384A1 (en) * 2003-07-15 2005-01-20 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
AU2003272082A1 (en) * 2003-10-07 2005-04-21 Biocon Limited Process for the production of atorvastatin calcium
JP2007517028A (ja) * 2003-12-29 2007-06-28 レツク・フアーマシユーテイカルズ・デー・デー 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法
EP1727795B1 (de) 2004-03-17 2012-02-15 Ranbaxy Laboratories Limited Verfahren zur herstellung von atorvastatin-calcium in amorpher form
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
ES2586561T3 (es) * 2004-07-16 2016-10-17 Lek Pharmaceuticals D.D. Productos de degradación oxidativa de atorvastatina calcio
MX2007000765A (es) 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
WO2006021969A1 (en) * 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
US20090099371A1 (en) * 2006-01-31 2009-04-16 Runjhun Gupta Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EA023338B1 (ru) * 2007-10-17 2016-05-31 Тодд Ф. Овокайтис Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
HUE030160T2 (en) * 2010-04-19 2017-05-29 Dsm Sinochem Pharm Nl Bv Preparation of atorvastatin with low dietary contamination
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
WO2015187974A1 (en) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
ES2167587T3 (es) * 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
CA2435954A1 (en) 2002-08-01
BG108017A (bg) 2004-08-31
US7074940B2 (en) 2006-07-11
IL157068A0 (en) 2004-02-08
BR0206637A (pt) 2004-08-03
SK9082003A3 (en) 2003-12-02
PL361763A1 (en) 2004-10-04
HUP0302797A2 (hu) 2003-11-28
DE60203894D1 (de) 2005-06-02
MXPA03006548A (es) 2004-10-15
RS51010B (sr) 2010-10-31
SI1373202T1 (sl) 2005-12-31
EP1373202A1 (de) 2004-01-02
CA2435954C (en) 2008-06-03
CN1487921A (zh) 2004-04-07
AU2002219455B2 (en) 2007-04-26
ZA200305307B (en) 2004-07-09
YU56803A (sh) 2006-05-25
EP1373202B1 (de) 2005-04-27
EE05270B1 (et) 2010-02-15
IL157068A (en) 2009-09-01
SI20814A (sl) 2002-08-31
DK1373202T3 (da) 2005-05-17
HRP20030575A2 (en) 2005-06-30
RU2003124962A (ru) 2005-01-10
KR20030077003A (ko) 2003-09-29
DE60203894T2 (de) 2006-01-19
HRP20030575B1 (en) 2011-10-31
US20040072895A1 (en) 2004-04-15
JP2005503997A (ja) 2005-02-10
SK286593B6 (sk) 2009-01-07
WO2002059087A1 (en) 2002-08-01
UA73829C2 (en) 2005-09-15
JP4336106B2 (ja) 2009-09-30
ES2240748T3 (es) 2005-10-16
CZ20031988A3 (cs) 2003-11-12
US20030109569A1 (en) 2003-06-12
HUP0302797A3 (en) 2009-09-28
CN1260213C (zh) 2006-06-21
RU2324679C2 (ru) 2008-05-20
KR100882066B1 (ko) 2009-02-10
PL209428B1 (pl) 2011-08-31
HU227535B1 (en) 2011-08-29
US6750353B2 (en) 2004-06-15
EE200300333A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
ATE294159T1 (de) Herstellung von nichtkristallinem atorvastatin?calcium
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
AUPR213700A0 (en) Antiviral agents
TR199901127T2 (xx) Antibakteriyel etkili 6-O-ikameli ketolitler.
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
WO2004096823A3 (en) Novel ketolide derivatives
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
DK0992509T3 (da) Nye makrolid-derivater
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
DK0808303T3 (da) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister
EP1329218A4 (de) Wirkstoffe zur vorbeugung und behandlung portaler hypertonie
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
AP9801235A0 (en) Erythromycin derivatives.
DE60008430D1 (de) Verbindungen mit antithrombotischer wirkung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373202

Country of ref document: EP